[ad_1]
Antibiotice Iași will deliver, in the next 12 months, 2,750,000 vials of AmoxiPlus (amoxicillin / clavulanic acid – sterile injectable powder), an antibiotic used to treat infections associated with COVID-19, in countries of the European Union, after winning a tender . organized by the European Commission. AmoxiPlus is one of the most widely used antibiotics in the pandemic, according to the company.
The European Commission recently finalized the tender to provide member countries with the necessary reserves for the second wave of the pandemic, with beta-lactam antibiotics (amoxicillin with clavulanic acid and piperacycline with tazobactam).
Antibiotice Iași has won this competition for the product AmoxiPlus (amoxicillin / clavulanic acid – sterile injectable powder) and will deliver, at the request of European countries, 2,750,000 vials within a period of 12 months.
The fight against the SARS-CoV-2 virus has determined that Europe takes safety measures with regard to the stocks of beta-lactam antibiotics administered by doctors around the world for the treatment of infections associated with Covid-19, show representatives of Antibiotice Iași.
Amoxicillin with clavulanic acid, together with piperacillin with tazobactam, are the main products recommended by the World Health Organization for anti-infective treatment.
Antibiotice is the only pharmaceutical company in Romania that has a production flow of sterile injectable powders, the first product was manufactured in 1955. The quality standards implemented in this production flow have been recognized and approved by the FDA (Food and Drug Administration). Medications) from the United States.
Produced for over 30 years, Antibiotice Iași sells this top-generation antibiotic in hospitals in Romania, Great Britain, Vietnam, Hungary, Lithuania, Iraq, and Yemen.
